{"id":976,"date":"2025-10-13T09:59:16","date_gmt":"2025-10-13T09:59:16","guid":{"rendered":"https:\/\/ardenneiratherm.com\/clinical-trials-whole-body-hyperthermia-wira\/"},"modified":"2025-12-19T08:27:55","modified_gmt":"2025-12-19T08:27:55","slug":"kliinilised-uuringud-hupertermia-onkoloogias","status":"publish","type":"page","link":"https:\/\/ardenneiratherm.com\/et\/kliinilised-uuringud-hupertermia-onkoloogias\/","title":{"rendered":"Kliinilised uuringud"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"976\" class=\"elementor elementor-976 elementor-756\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ea8f7b2 e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"ea8f7b2\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInDown&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f3c7e79 elementor-widget elementor-widget-heading\" data-id=\"f3c7e79\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Kogu Keha H\u00fcpertermia (WBH) Onkoloogias ja Muudes Patoloogiates: Konsolideeritud S\u00fcnergia, Immunomoduleerimine ja Kliinilised uuringud<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c02c88e animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"c02c88e\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header><p><strong>Avaldatud:\u00a0<time datetime=\"2025-10-13\">2025-10-13<\/time>\u00a0| Viimati Muudetud:\u00a0<time datetime=\"2025-10-13\">2025-10-13<\/time><\/strong><\/p><\/header><div class=\"authors\"><p>Autorid:<br \/><a href=\"https:\/\/ardenneiratherm.com\/et\/our-team\/veronica-iatan-hupertermia-arst\/\">Veronica Iatan, M.D.<\/a>,<br \/><a href=\"https:\/\/ardenneiratherm.com\/et\/our-team\/cristian-gologan\/\">Cristian Gologan, M.Sc.<\/a><\/p><\/div><section class=\"ai-summary\"><p><strong>Kogu Keha H\u00fcpertermia (WBH)<\/strong> on s\u00fcsteemne onkoloogiline strateegia, mis h\u00f5lmab keha keskse temperatuuri kontrollitud t\u00f5stmist, sageli kasutades <strong>Veega Filtreeritud Infrapuna-A (wIRA)<\/strong> tehnoloogiat. WBH on peamiselt <strong>Kemo\/Radio-sensibilisaator<\/strong>, mis parandab oluliselt kasvaja perfusiooni ja hapnikuga varustamist, et v\u00f5imendada traditsiooniliste ravimeetodite t\u00f5husust. Oluline on ka see, et see toimib tugeva <strong>S\u00fcsteemse Immunomodulaatorina<\/strong>, mobiliseerides Kuumastressi Valgud (HSP) ja T-rakud. See tegevus loob olulise s\u00fcnergia arenenud <strong>Immunoteraapiaga (ICI)<\/strong>\u00a0ja pakub dramaatilist, kiiret valu leevendust ning olulist Elukvaliteedi (EK) paranemist erinevat t\u00fc\u00fcpi v\u00e4hi ja krooniliste seisundite, n\u00e4iteks fibrom\u00fcalgia korral.<\/p><\/section><section class=\"disclaimer\"><strong>Meditsiiniline Hoiatus: See artikkel on m\u00f5eldud ainult teavitamise eesm\u00e4rgil ega asenda mingil juhul individuaalset arstlikku konsultatsiooni, diagnoosi v\u00f5i ravi, mille on m\u00e4\u00e4ranud litsentseeritud arst.<\/strong><\/section><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-805e6aa e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"805e6aa\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-67bd9be elementor-widget elementor-widget-heading\" data-id=\"67bd9be\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">1. Kogu Keha H\u00fcpertermia (WBH) ja Terapeutilise Tehnoloogia Definitsioon<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-67346b0 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"67346b0\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p style=\"text-align: left;\"><strong>Kogu Keha H\u00fcpertermia (WBH)<\/strong> ehk \u201cs\u00fcsteemne h\u00fcpertermia\u201d on m\u00e4\u00e4ratletud kui keha keskse temperatuuri kontrollitud t\u00f5stmine terapeutilistel eesm\u00e4rkidel. Tuginedes <strong>loomuliku palaviku m\u00f5jude spektrile erinevatel temperatuuridel<\/strong>, eristatakse WBH protseduure j\u00e4rgmiselt:<\/p><ul style=\"text-align: left;\"><li><strong>Kerge WBH:<\/strong> &lt; 38,5\u00b0C<\/li><li><strong>M\u00f5\u00f5dukas WBH:<\/strong> 38,5\u00b0C \u2013 40,5 \u00b0C<\/li><li><strong>Ekstreemne WBH:<\/strong> &gt; 40,5\u00b0C<\/li><\/ul><p style=\"text-align: left;\">Eelk\u00f5ige kerge ja m\u00f5\u00f5dukas WBH <strong>suurendab verevoolu (perfusiooni),<\/strong>\u00a0stimuleerib ainevahetust, v\u00e4hendab lihastoonust ja <strong class=\"key-term\">stimuleerib immuuns\u00fcsteemi.<\/strong><\/p><p style=\"text-align: left;\"><a title=\"Von Ardenne IRATHERM\u00ae 1000M WBH wIRA seadme tehnilised detailid\" href=\"https:\/\/ardenneiratherm.com\/et\/ardenne-iratherm-hupertermia-seade\/\">von Ardenne IRATHERM\u00ae 1000M WBH wIRA seade<\/a> kasutab selleks otstarbeks eranditult <strong>s\u00fcgavale tungivat,<\/strong> <strong>nahas\u00f5bralikku, veega filtreeritud Infrapuna-A (wIRA) soojuskiirgust<\/strong>\u00a0(ilma IR-B \/ IR-C). Selle avatud, mitte-klaustrofoobne disain tagab \u00fchtlase kiirgusintensiivsuse \u00fcle Terve patsiendi pinna (selg) ja pakub kasutajale optimaalset, patsiendispetsiifilist soojusvarustust nii asukoha kui ka intensiivsuse osas.<\/p><p style=\"text-align: left;\">Veega filtreeritud Infrapuna-A kiirgus vastab p\u00e4ikese loomulikule soojuskiirgusele ja moodustab tehnoloogilise aluse \u00fchtlaseks ja \u00f5rnaks soojuse rakendamiseks[1,5,7,8].<\/p><p style=\"text-align: left;\">Kasutades von Ardenne IRATHERM<sup>\u00ae<\/sup>\u00a01000 p\u00f5him\u00f5tet, mida on arendatud ja t\u00f5estatud \u00fcle 30 aasta, \u00f5nnestus\u00a0<a title=\"Prof. Manfred von Ardenne - Panused\" href=\"https:\/\/ardenneiratherm.com\/et\/our-team\/manfred-von-ardenne\/\">Prof. Manfred von Ardenne<\/a>\u00a0see soojuskiirgus f\u00fc\u00fcsikaliselt ja tehniliselt reprodutseerida ning teha see t\u00f6\u00f6stuslikult k\u00e4ttesaadavaks p\u00fcsivaks meditsiiniliseks kasutamiseks Kogu keha h\u00fcpertermia kaudu.<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6c924fa elementor-invisible elementor-widget elementor-widget-image\" data-id=\"6c924fa\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;zoomIn&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/ardenneiratherm.com\/wp-content\/uploads\/2025\/10\/von-Ardenne-Iratherm-10000-WBH-wIRA-hyperthermia-device-wIRA.jpg\" title=\"\" alt=\"von Ardenne Iratherm 10000 WBH wIRA hyperthermia-device-wIRA\" loading=\"lazy\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-48fd6d3 e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"48fd6d3\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-aafa804 elementor-widget elementor-widget-heading\" data-id=\"aafa804\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">2. Teaduslikud Alused ja S\u00fcsteemsed M\u00f5jud<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-672df30 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"672df30\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p style=\"text-align: left;\">WBH on arenenud strateegiaks, mis p\u00f5hineb kindlatel biof\u00fc\u00fcsikalistel ja f\u00fcsioloogilistel printsiipidel. Onkoloogias keskendutakse <strong>M\u00f5\u00f5dukale<\/strong> ja <strong>Palavikualapi H\u00fcpertermiale (HRV-WBH)<\/strong>, mida tunnustatakse mitme terapeutilise n\u00e4idustusega ravimeetoditena[1,3].<\/p><p style=\"text-align: left;\">\u00dchtlase ja \u00f5rna soojuse rakendamise tehnoloogilise aluse annavad sageli seadmed, mis kasutavad <strong>Veega Filtreeritud Infrapuna-A (wIRA) kiirgust<\/strong>. Detailne biof\u00fc\u00fcsikaline uuring on kinnitanud <strong>selle tehnoloogia v\u00f5imet tagada s\u00fcgav ja kontrollitud soojendamine<\/strong>, arvestades naha optilisi omadusi ja fotobioloogilist alust doseerimiseks[5,7,8].<\/p><p style=\"text-align: left;\">Detailne biof\u00fc\u00fcsikaline uuring on kinnitanud\u00a0<strong class=\"key-term\">wIRA-tehnoloogia v\u00f5imet<\/strong> tagada <strong>s\u00fcgav ja kontrollitud soojendamine<\/strong>[5,7,8]. F\u00fcsioloogilisel tasandil on WBH-l p\u00f5hilised s\u00fcsteemsed m\u00f5jud:<\/p><ol style=\"text-align: left;\"><li><strong>Paranenud Vere Reoloogia:<\/strong> IR-WBH-ga kokkupuude m\u00f5jutab soodsalt vere vooluomadusi ja hemod\u00fcnaamikat, toetades olulist mehhanismi <strong>kasvaja perfusiooni paranemiseks<\/strong>\u00a0\u2014 kriitiline eeltingimus s\u00fcsteemsete ravimeetodite edukusele[2].<\/li><li><strong>\u00dcldine Bioloogiline Aktiveerimine:<\/strong> WBH kutsub esile kuumastressi vastuse, mis k\u00e4ivitab bioloogiliste protsesside kaskaadi, sealhulgas <strong>hormonaals\u00fcsteemi moduleerimise<\/strong> ja <strong>ainevahetuse kiirenemise<\/strong>[4,6[.<\/li><\/ol><p style=\"text-align: left;\">Nendel alustel toimib WBH\u00a0<strong class=\"key-term\">s\u00fcsteemse immunomodulaatorina<\/strong>, optimeerides\u00a0<strong class=\"key-term\">Kasvaja Mikromilj\u00f6\u00f6d (KMM)<\/strong> ja <strong>v\u00f5imendades arenenud onkoloogiliste ravimeetodite t\u00f5husust<\/strong>[9].<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-73d38c1 e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"73d38c1\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4061817 elementor-widget elementor-widget-heading\" data-id=\"4061817\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">3. Peamised Toimemehhanismid (Molekulaarsed, F\u00fcsioloogilised ja Immunoloogilised)<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22327e2 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"22327e2\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p style=\"text-align: left;\">WBH terapeutilised m\u00f5jud on keerulised, vahendatud muutustest raku-, immuun- ja f\u00fcsioloogilisel tasandil:<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5638fef animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"5638fef\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div style=\"text-align: center;\"><div><div><div><div><header><div style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">A. S\u00fcnergia Kemoteraapia ja Kiiritusraviga (Kemo\/Radio-sensibilisaator)<\/h3><ul><li style=\"text-align: left;\"><strong>Kasvaja Mikromilj\u00f6\u00f6 (KMM) Optimeerimine:<\/strong> WBH parandab <strong>kasvaja vereperfusiooni<\/strong> ja <strong>hapnikuga varustamist<\/strong>, p\u00f6\u00f6rates seel\u00e4bi \u00fcmber kasvaja h\u00fcpoksia. See on \u00fclioluline, sest h\u00e4sti hapnikuga varustatud kasvajarakud on oluliselt tundlikumad h\u00e4vitamisele <strong>Kemoteraapia<\/strong> (KT) ja <strong>Kiiritusravi<\/strong> (KR) abil[9,41].<\/li><li style=\"text-align: left;\"><strong>Kemo\/Radio T\u00f5husus:<\/strong>\u00a0H\u00fcpertermia toimib\u00a0<strong>kemo &amp; radio sensibilisaatorina<\/strong>, parandades hapniku kohaletoimetamist kasvajale (radio-sensibiliseeriv m\u00f5ju) ja suurendades selliste ravimite nagu Cisplatiin, Gemtsitabiin ja Karboplatiin t\u00f5husust[12, 16, 36].<\/li><\/ul><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3119e45 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"3119e45\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div style=\"text-align: center;\"><div><div><div><div><header><div style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">B. Tugeva Kasvajavastase Immuunvastuse Indutseerimine (Immunomoduleerimine)<\/h3><p style=\"text-align: left;\">WBH on keha kaitses\u00fcsteemi tugev aktivaator:<\/p><ul><li style=\"text-align: left;\"><strong>Kuumastressi Valgud (HSP):<\/strong> Kuumastress stimuleerib <strong>HSP70<\/strong> s\u00fcnteesi ja vabanemist. Need valgud toimivad \u201cohusignaalidena\u201d, mis m\u00e4rgistavad v\u00e4hirakud immuuns\u00fcsteemi <strong>Ts\u00fctotoksiliste T-L\u00fcmfots\u00fc\u00fctide (CTL)<\/strong>\u00a0poolt toimuva tugevdatud r\u00fcnnaku jaoks[9, 10, 29]..<\/li><li style=\"text-align: left;\"><strong>V\u00f5tme Immuunrakkude Aktiveerimine:<\/strong>\u00a0Temperatuurivahemik 39\u201343\u00b0C suurendab <b>Loomulike Tapjarakkude (NK) rakkude<\/b>\u00a0aktiivsust ja soodustab <b>abistaja- ja ts\u00fctotoksiliste T-l\u00fcmfots\u00fc\u00fctide<\/b>, <b>dendriitrakkude<\/b>\u00a0ja <b>makrofaagide<\/b>\u00a0aktiivsust, samal ajal kui\u00a0v\u00f5imalikult kompromiteerib immunosupressiivseid rakke[9, 10, 11, 25, 26]..<\/li><li style=\"text-align: left;\"><strong>T-L\u00fcmfots\u00fc\u00fctide Suurenemine:<\/strong>\u00a0HRV-WBH v\u00f5ib <b>oluliselt suurendada (nt 3-kordselt)<\/b>\u00a0ts\u00fctotoksiliste T-l\u00fcmfots\u00fc\u00fctide populatsiooni l\u00fcmfoidorganites, <b>tugevdades seel\u00e4bi s\u00fcsteemset kasvajavastast immuunr\u00fcnnakut[10]<\/b>.<\/li><li style=\"text-align: left;\"><strong>Vaktsiinid ja APC-d:<\/strong>\u00a0WBH v\u00f5ib reguleerida Antigeeni Esitlevate Rakkude (APC) funktsiooni ja suurendada v\u00e4hivaktsiinide, sealhulgas HSP110 ja GRP170-l p\u00f5hinevate vaktsiinide t\u00f5husust[27,37].<\/li><\/ul><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-bbbd880 animated-slow e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"bbbd880\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e99507b elementor-widget elementor-widget-heading\" data-id=\"e99507b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">4. Kliiniline T\u00f5endus ja S\u00fcnergia Multimodaalses Teraapias<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e6a66ba animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"e6a66ba\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">A. S\u00fcnergia Immunoteraapiaga (Immuunpunkti Inhibiitorid \u2013 ICI)<\/h3><p style=\"text-align: left;\">Retrospektiivne juhtumite seeria 131 kaugelearenenud (IV staadium) kartsinoomiga patsiendiga uuris multimodaalset protokolli, mis h\u00f5lmas *Kogu keha h\u00fcpertermiat* lisaks immuunpunkti inhibiitoritele (Ipilimumab, Nivolumab) ja IL-2.[18]<\/p><p style=\"text-align: left;\"><strong>Peamine J\u00e4reldus:<\/strong> WBH wIRA m\u00e4\u00e4ratleti <strong>integreeriva ja olulise komponendina<\/strong>, mis <strong>maksimeerib kasvajavastast immuunvastust<\/strong>. <strong>WBH aktiveerib ja mobiliseerib T-l\u00fcmfots\u00fc\u00fcte (indutseerides HSP70 ja vabastades kasvaja antigeene)<\/strong>; immuunpunkti inhibiitorid \u201cvabastavad seej\u00e4rel piduri\u201d nendelt eelnevalt aktiveeritud T-l\u00fcmfots\u00fc\u00fctidelt, mis viib ebatavaliselt k\u00f5rge soodsa kliinilise ravivastuse m\u00e4\u00e4rani kaugelearenenud haiguse korral.[18]<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-464662f animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"464662f\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">B. Kliinilised Rakendused Erinevate V\u00e4hivormide Korral<\/h3><ul><li style=\"text-align: left;\"><strong>Pankrease V\u00e4hk (K\u00f5hun\u00e4\u00e4rmev\u00e4hk):<\/strong>\u00a0Faas I-II protokollid, mis kasutasid kerget WBH-d (HRV-WBH) kombinatsioonis kemoteraapia ja Interferoon-alfaga, on n\u00e4idanud <strong>v\u00e4hemalt 50% kasvaja taandumist peaaegu pooltel raviraskustega patsientidel[4.22]<\/strong>.<\/li><li style=\"text-align: left;\"><strong>Rinnav\u00e4hk (Retsidiiv):<\/strong>\u00a0WBH koos korduvkiirituse v\u00f5i kiiritusraviga on n\u00e4idanud t\u00f5husust lokaalselt kaugelearenenud rinnav\u00e4hi ja rinnaseina retsidiivi korral, mida kinnitavad randomiseeritud andmed[39,40].<\/li><li style=\"text-align: left;\"><strong>Munasarjav\u00e4hk (Ovariaalv\u00e4hi):<\/strong>\u00a0WBH kombinatsioonis <b>karboplatiiniga<\/b>\u00a0on uuritud Faas II uuringus korduva munasarjav\u00e4hi korral[16,20].<\/li><li style=\"text-align: left;\"><strong>Kolorektaalv\u00e4hk:\u00a0<\/strong>WBH wIRA-d on kasutatud von Ardenne S\u00fcsteemse V\u00e4hivastase Mitmeastmelise Teraapia (sCMT) kontekstis koos kemoteraapiaga Faas I\/II uuringus.[15]<\/li><\/ul><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4cb34f6 e-con-full animated-slow e-flex elementor-invisible e-con e-child\" data-id=\"4cb34f6\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c7ca566 elementor-widget elementor-widget-heading\" data-id=\"c7ca566\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">5. Kiire Valu Leevendamine ja Elukvaliteedi (EK) Oluline Paranemine<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8ec3c40 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"8ec3c40\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p style=\"text-align: left;\">Patsiendid v\u00f5ivad kogeda kiiret valu leevendust ja \u00fcldise heaolu paranemist, nagu t\u00e4heldati dr. Bulli uuringus ja eriti Sahinbas et al. uuemas Faas III kliinilises uuringus.[14]<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cfebbf0 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"cfebbf0\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">Faas III Kliiniline Uuring (2024) Luumetastaaside Korral<\/h3><div class=\"container\" style=\"text-align: left;\"><div class=\"section\"><section><span dir=\"auto\">Aastal\u00a0<\/span><a title=\"Faas III uuring Sahinbas 2024\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0306456524000226\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\">2024 avaldasid Sahinbas ja kolleegid Faas III uuringu<\/span><\/a><span dir=\"auto\">\u00a0luumetastaaside valude kohta, peamiselt rinna- ja eesn\u00e4\u00e4rmev\u00e4hi korral, kasutades WBH wIRA Iratherm h\u00fcpertermia seadmeid ST lisana.<\/span><span dir=\"auto\">Selle uuringu p\u00f5hjal esindas ainult ST r\u00fchm k\u00f5ige intensiivsemat valu. Uuring l\u00f5petati p\u00e4rast kokku 61 patsiendi kaasamist, 5 aastat p\u00e4rast esimest registreerimist (aprill 2016 \u2013 veebruar 2021). L\u00f5puks n\u00e4itas t\u00e4ieliku ravivastuse (TR) m\u00e4\u00e4r ST + WBH r\u00fchmas k\u00f5ige olulisemat erinevust v\u00f5rreldes ainult ST-ga: <b>47,4 % vs. 5,3 %<\/b>, vastavalt, <b>2 kuu jooksul p\u00e4rast ravi<\/b>\u00a0(P-v\u00e4\u00e4rtus &lt; 0,05). Aeg t\u00e4ieliku valu leevendamiseni oli ST + WBH puhul 10 p\u00e4eva, samas kui ainult ST r\u00fchmas seda l\u00f5pp-punkti ei saavutatud. Valu progresseerumist v\u00f5i haiguse stabiilsust t\u00e4heldati pooltel ST r\u00fchma patsientidel 4 n\u00e4dala jooksul p\u00e4rast ravi. Kuid <b>see n\u00e4itaja oli ST + WBH patsientidel kahe kuu jooksul p\u00e4rast ravi nullil\u00e4hedane<\/b>.<\/span><strong class=\"sub-title\"><span dir=\"auto\">J\u00e4reldused:\u00a0<\/span><\/strong><span dir=\"auto\">\u00a0WBH pluss ST n\u00e4itas olulist suurenemist valu leevendamises ja l\u00fchemat reageerimisaega v\u00f5rreldes ainult ST-ga patsientidel, kellel on metastaatilised luukahjustused.<\/span><\/section><\/div><\/div><div class=\"table-scroll-wrapper\"><table border=\"1\"><thead><tr><th><span dir=\"auto\">EK Indikaator\/Valu Paranemine<\/span><\/th><th><span dir=\"auto\">ST Monoteraapia<\/span><\/th><th><span dir=\"auto\">ST + H\u00fcpertermia (WBH wIRA)<\/span><\/th><th><span dir=\"auto\">M\u00f5ju EK-le<\/span><\/th><\/tr><\/thead><tbody><tr><td><strong><span dir=\"auto\">T\u00e4ielik ravivastus (TR) 2 kuu p\u00e4rast<\/span><\/strong><span dir=\"auto\">\u00a0(null valu skoor)<\/span><\/td><td>5,3 %<\/td><td><b>47,4 %<\/b><\/td><td><span dir=\"auto\">*\u00a0<\/span><strong><span dir=\"auto\">894% suurenemine<\/span><\/strong><span dir=\"auto\">\u00a0* t\u00e4ieliku valu k\u00f5rvaldamise v\u00f5imaluses.<\/span><\/td><\/tr><tr><td><strong><span dir=\"auto\">Aeg t\u00e4ieliku valu leevendamiseni<\/span><\/strong><\/td><td><span dir=\"auto\">saavutamata<\/span><\/td><td><span dir=\"auto\"><b>10 p\u00e4eva<\/b><\/span><\/td><td><span dir=\"auto\"><strong>\u201coluline ja kiire\u201d<\/strong>\u00a0\u00a0kasu<\/span><\/td><\/tr><tr><td style=\"text-align: left;\"><strong><span dir=\"auto\">Valu Leevenduse Kestus\u00a0<\/span><\/strong><\/td><td style=\"text-align: left;\"><span dir=\"auto\">Mediaan: 28 p\u00e4eva\/4 n\u00e4dalat pooltel patsientidel<\/span><\/td><td style=\"text-align: left;\"><span dir=\"auto\">Mediaan: <b>Saavutamata 24 n\u00e4dala jooksul<\/b><\/span><\/td><td style=\"text-align: left;\"><span dir=\"auto\">Leevenduse kestus on *\u00a0<\/span><strong><span dir=\"auto\">kuus korda pikem<\/span><\/strong><span dir=\"auto\">\u00a0*, v\u00e4hendades s\u00f5ltuvust valuvaigistitest.<\/span><\/td><\/tr><\/tbody><\/table><\/div><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e97cd55 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"e97cd55\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p>V\u00f5rreldes sarnase\u00a0<a title=\"Faas III uuring Chi MS et al. 2017\" href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\">\u00a0Faas III uuringuga, mille avaldas Chi MS et al<\/a><span dir=\"auto\">\u00a0. (2017) RF lokoregionaalse h\u00fcpertermia kohta, olid eelised (<em>EK ja valu v\u00e4hendamise osas)<\/em>\u00a0saavutatud WBH wIRA h\u00fcpertermia abil oluliselt paremad \u2013 RF HT + ST uuringu tulemused:<\/span><\/p><div class=\"table-scroll-wrapper\"><table border=\"1\"><thead><tr><th><span dir=\"auto\">EK Indikaator\/Valu Paranemine<\/span><\/th><th><span dir=\"auto\">ST Monoteraapia<\/span><\/th><th><span dir=\"auto\">ST + H\u00fcpertermia (HT)<\/span><\/th><th>M\u00f5ju EK-le<\/th><\/tr><\/thead><tbody><tr><td><strong><span dir=\"auto\">T\u00e4ielik ravivastus (TR) 3 Kuu P\u00e4rast<\/span><\/strong><span dir=\"auto\">\u00a0(null valu skoor)<\/span><\/td><td>7,1 %<\/td><td>37,9 %<\/td><td><span dir=\"auto\">533% suurenemine t\u00e4ieliku valu leevendamise v\u00f5imaluses.<\/span><\/td><\/tr><tr><td><strong><span dir=\"auto\">Valu Leevenduse Kestus<\/span><\/strong><\/td><td><span dir=\"auto\">Mediaan: 55 p\u00e4eva\/7,9 n\u00e4dalat<\/span><\/td><td><span dir=\"auto\">Mediaan: Saavutamata 24 n\u00e4dala jooksul<\/span><\/td><td><span dir=\"auto\">Leevenduse kestus kolmekordistub, v\u00e4hendades s\u00f5ltuvust valuvaigistitest.<\/span><\/td><\/tr><\/tbody><\/table><\/div><p>\u00a0<\/p><p>Kokkuv\u00f5ttes kinnitab konsolideeritud teaduslik t\u00f5endus (alates wIRA-tehnoloogia p\u00f5hiuuringutest kuni v\u00f5tmet\u00e4htsusega Faas III kliiniliste uuringuteni) WBH rolli adjuvandina mitmetahulise m\u00f5juga onkoloogias: *see suurendab KT\/ST t\u00f5husust, aktiveerib s\u00fcsteemset immuuns\u00fcsteemi (kaasa arvatud s\u00fcnergia immunoteraapiaga) ja parandab dramaatiliselt valu kontrolli ja EK-d* v\u00e4hihaigetel.<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-2b9b952 e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"2b9b952\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-9003cfd elementor-widget elementor-widget-heading\" data-id=\"9003cfd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">6. S\u00fcsteemsed F\u00fcsioloogilised Eelised ja Terapeutiline Potentsiaal Muudes Patoloogiates<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0307397 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"0307397\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p>WBH wIRA-kiirgusega pakutav kerge, kontrollitud soojus k\u00e4ivitab keerulisi termoregulatoorseid vastuseid, mis loovad laialdasi s\u00fcsteemseid eeliseid, laiendades terapeutilist potentsiaali ka v\u00e4ljapoole onkoloogiat:<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f8b16cd animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"f8b16cd\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">A. Lihas-Skeleti Seisundite ja Valu Ravi<\/h3><p style=\"text-align: left;\">WBH on efektiivne krooniliste valus\u00fcndroomide haldamisel, kasutades \u00e4ra oma f\u00fcsioloogilist m\u00f5ju lihastoonusele ja mikrotsirkulatsioonile:<\/p><ul><li style=\"text-align: left;\"><strong>Dorsalgia (Krooniline Seljavalu):<\/strong>\u00a0Uuringud n\u00e4itavad, et kerge WBH koos statsionaarse multimodaalse valuraviga annab olulist kasu patsientidele kroonilise mittespetsiifilise alaseljavaluga (dorsalgia)[53,54].<\/li><li style=\"text-align: left;\"><strong>Fibrom\u00fcalgia S\u00fcndroom (FMS):<\/strong>\u00a0WBH on dokumenteeritud FMS-i t\u00e4iendav ravi. Randomiseeritud kontrollitud uuringud on n\u00e4idanud kerge wIRA WBH efektiivsust standardsetes multimodaalsetes taastusraviseadetes, m\u00f5jutades <b>valu intensiivsust<\/b>\u00a0ja <b>vaimset seisundit<\/b>. See kasu on osaliselt seotud paranenud mikrotsirkulatsiooniga, mis on FMS-patsientidel teadaolev probleem[55].<\/li><li style=\"text-align: left;\"><strong>Ank\u00fcloseeriv Spond\u00fcliit (AS):<\/strong>\u00a0WBH on n\u00e4idanud immunomoduleerivat m\u00f5ju AS-patsientidel, uuringud teatavad WBH v\u00f5imest suurendada p\u00f5letikuvastaseid mediaatoreid nagu *<b>Interleukiin-10<\/b>* (IL-10) ja moduleerida p\u00f5letikueelset ts\u00fctokiini nagu TNF-\u03b1, mis viitab soodsale rollile selle seisundiga seotud kroonilise p\u00f5letiku haldamisel.[52,58,59]<\/li><li style=\"text-align: left;\"><strong>Raynaud\u2019 Fenomen S\u00fcsteemse Skleroosi Korral:<\/strong>\u00a0Infrapunap\u00f5hine h\u00fcpertermia on osutunud efektiivseks sklerodermiaga seotud Raynaud\u2019 fenomeni vasokonstriktsiooniliste s\u00fcmptomite ravimisel, demonstreerides vaskulaarseid eeliseid.49]<\/li><\/ul><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b0c1b89 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"b0c1b89\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">B. Kardiovaskulaarne ja Vereringe Tervis \u2764\ufe0f<\/h3><p style=\"text-align: left;\">Lisaks kasvaja perfusiooni parandamisele on WBH-l spetsiifilised m\u00f5jud vereringes\u00fcsteemile:<\/p><ul><li style=\"text-align: left;\"><strong>Essentsiaalne H\u00fcpertensioon:<\/strong>\u00a0Mitmed uuringud on uurinud kerge IR-A h\u00fcpertermia kasutamist arteriaalse h\u00fcpertensiooniga patsientidel (WHO I ja II staadium). Tulemused viitavad sellele, et j\u00e4rjestikused ravimeetodid v\u00f5ivad positiivselt m\u00f5jutada <b>tsentraalseid ja perifeerseid pulsilaineid<\/b>, verer\u00f5hku ja <b>vere viskoossust<\/b>, kinnitades WBH rolli mittefarmakoloogilise f\u00fcsioteraapia v\u00f5imalusena.[44,47]<\/li><\/ul><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ce4fdb9 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"ce4fdb9\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \" style=\"text-align: left;\"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">C. Neuro-Endokriinsed ja Ps\u00fchholoogilised M\u00f5jud<\/h3><p style=\"text-align: left;\">WBH kaasab keha neuro-endokriins\u00fcsteeme, m\u00f5jutades meeleolu ja ainevahetust:<\/p><ul><li style=\"text-align: left;\"><strong>Suur Depressiivne H\u00e4ire (SDH):<\/strong> Randomiseeritud kliiniline uuring n\u00e4itas, et \u00fcks WBH-seanss v\u00f5ib toimida kiiretoimelise antidepressandina, p\u00f5hjustades depressiivsete s\u00fcmptomite v\u00e4henemise mitme n\u00e4dala jooksul. See m\u00f5ju on seotud soojuse poolt indutseeritud immuun- ja p\u00f5letikuteede aktiveerimisega, mis m\u00f5jutavad aju[51].<\/li><li style=\"text-align: left;\"><strong>Hormonaalne Moduleerimine (Endokrinoloogia):<\/strong> WBH stimuleerib <strong>H\u00fcpotalamuse-H\u00fcpof\u00fc\u00fcsi-Neerupealise (HPA) telge<\/strong> ja m\u00f5jutab hormoonitaset. Uuringud on dokumenteerinud <strong>Kasvuhormooni<\/strong>\u00a0ja <strong>Prolaktiini<\/strong> reaktsioone Kogu keha h\u00fcpertermia ajal, r\u00f5hutades selle m\u00f5ju endokriinsele regulatsioonile.[42,43]<\/li><li style=\"text-align: left;\"><strong>Ainevahetus ja Raku Vastus:<\/strong> WBH kiirendab basaalse ainevahetuse kiirust. Rakutasandil m\u00f5jutab soojus pO2-kineetikat ja on seotud kaitsvate valkude, nagu <strong>ferritiin<\/strong> naha s\u00fcnteesiga, toetades kudede taastumist.[46,48]<\/li><\/ul><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-91f7153 elementor-invisible elementor-widget elementor-widget-image\" data-id=\"91f7153\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;zoomIn&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/ardenneiratherm.com\/wp-content\/uploads\/2025\/10\/von-Ardenne-Iratherm-10000-WBH-wIRA-hyperthermia-device-summary.jpg\" title=\"\" alt=\"von Ardenne Iratherm 10000 WBH wIRA hyperthermia-device-summary\" loading=\"lazy\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-ae37e3c e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"ae37e3c\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a7dda12 elementor-widget elementor-widget-heading\" data-id=\"a7dda12\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Korduma Kippuvad K\u00fcsimused (KKK) Soovitatud WBH Seansside ja Sihttemperatuuride Kohta<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-aa3b4f4 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"aa3b4f4\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" data-delay=\"0\"><p><i>Ravi\u00a0<\/i><i>tuleb<\/i>\u00a0<i>teostada<\/i><i>\u00a0ainult p\u00e4rast\u00a0<\/i><i>l\u00f5plikku<\/i>\u00a0<i>konsultatsiooni<\/i>\u00a0<i>arstiga<\/i><\/p><\/div><\/header><div><h4>\u00a0<\/h4><\/div><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-968c093 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"968c093\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" data-delay=\"0\"><h3>\u00a0<\/h3><\/div><\/header><div><h4>Milline on soovitatav Kogu Keha H\u00fcpertermia (WBH) protokoll Essentsiaalse H\u00fcpertensiooni Korral?<\/h4><div><p>Essentsiaalse H\u00fcpertensiooni protokoll soovitab 12 seanssi sihttemperatuuriga 38,3 \u00b0C. Iga seanss kestab umbes 45 minutit, sisaldades 30-minutilist temperatuuri t\u00f5stmise faasi ja 15-minutilist puhkefaasi (ilma platoofaasita).<\/p><\/div><\/div><div><h4>Millised on soovitatavad WBH parameetrid Kroonilise Seljavalu (Dorsalgia) Korral?<\/h4><div><p>Dorsalgia korral soovitatakse tavaliselt 6 seanssi, sihttemperatuuriga 38,4 \u00b0C. Koguseansi aeg on umbes 90 minutit, sisaldades 45 minutit temperatuuri t\u00f5stmist, 15-minutilist platoofaaasi ja 30 minutit puhkust.<\/p><\/div><\/div><div><h4>Milline on WBH protokoll Fibrom\u00fcalgia ja Ank\u00fcloseeriva Spond\u00fcliidi Korral?<\/h4><div><p>Nii Fibrom\u00fcalgia kui ka Ank\u00fcloseeriv Spond\u00fcliit j\u00e4rgivad tavaliselt 6 seansi protokolli, sihttemperatuuriga 38,5 \u00b0C. Koguseansi aeg on umbes 90 minutit, sisaldades 45 minutit temperatuuri t\u00f5stmist, 15-minutilist platoofaaasi ja 30 minutit puhkust.<\/p><\/div><\/div><div><h4>Milline on soovitatav protokoll WBH jaoks V\u00e4hiravi T\u00e4iendusena?<\/h4><div><p>V\u00e4hiravi t\u00e4iendusena n\u00f5uab protokoll 2 v\u00f5i enam seanssi siht-s\u00fcdamiku temperatuuriga 39,0 \u00b0C kuni 40,0 \u00b0C. Koguseansi aeg on pikim, vahemikus 3 kuni 4 tundi, mis h\u00f5lmab 60\u201390 minutit t\u00f5stmisfaasile, 60\u201390 minutit platoofaasie ja 60 minutit puhkefaasile.<\/p><\/div><\/div><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3875720 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"3875720\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><div><div class=\"wpb_content_element \"><div><div><div><div class=\"wpb_content_element \"><div><div><p>.<\/p><\/div><\/div><div class=\"table-scroll-wrapper\"><table width=\"1151\"><tbody><tr><td width=\"278\">N\u00e4idustus<\/td><td width=\"99\">Seansside arv<\/td><td width=\"135\">Sihttemperatuur<\/td><td colspan=\"2\" width=\"309\">Ravi aeg<br \/>T\u00f5stmise faas\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Platoo faas<\/td><td width=\"164\">Puhkeaeg<br \/>Puhke faas<\/td><td width=\"164\"><b>Kogu<\/b><br \/><b>WBH Seansi Aeg<\/b><\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Essentsiaalne H\u00fcpertensioon<\/td><td rowspan=\"2\" width=\"99\">12<\/td><td rowspan=\"2\" width=\"135\">38,3 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>30 min<\/b><\/td><td rowspan=\"2\" width=\"164\">15 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 45 min<\/b><\/td><\/tr><tr><td width=\"155\">30 min<\/td><td width=\"155\">0 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Dorsalgia<\/td><td rowspan=\"2\" width=\"99\">6<\/td><td rowspan=\"2\" width=\"135\">38,4 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>60 min<\/b><\/td><td rowspan=\"2\" width=\"164\">30 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 90 min<\/b><\/td><\/tr><tr><td width=\"155\">45 min<\/td><td width=\"155\">15 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Fibrom\u00fcalgia<\/td><td rowspan=\"2\" width=\"99\">6<\/td><td rowspan=\"2\" width=\"135\">38,5 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>60 min<\/b><\/td><td rowspan=\"2\" width=\"164\">30 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 90 min<\/b><\/td><\/tr><tr><td width=\"155\">45 min<\/td><td width=\"155\">15 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Ank\u00fcloseeriv Spond\u00fcliit<\/td><td rowspan=\"2\" width=\"99\">6<\/td><td rowspan=\"2\" width=\"135\">38,5 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>60 min<\/b><\/td><td rowspan=\"2\" width=\"164\">30 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 90 min<\/b><\/td><\/tr><tr><td width=\"155\">45 min<\/td><td width=\"155\">15 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">S\u00fcsteemne Skleroos<\/td><td rowspan=\"2\" width=\"99\">15<\/td><td rowspan=\"2\" width=\"135\">38,3 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>30 min<\/b><\/td><td rowspan=\"2\" width=\"164\">15 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 45 min<\/b><\/td><\/tr><tr><td width=\"155\">30 min<\/td><td width=\"155\">0 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Suur Depressiivne H\u00e4ire<\/td><td rowspan=\"2\" width=\"99\">1+<\/td><td rowspan=\"2\" width=\"135\">38,5 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>105 -170 min<\/b><\/td><td rowspan=\"2\" width=\"164\">30 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 2-3\u00a0<\/b><b>tundi<\/b><\/td><\/tr><tr><td width=\"155\">45-110 min<\/td><td width=\"155\">60 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">V\u00e4hiravi T\u00e4iendus<\/td><td rowspan=\"2\" width=\"99\">2+<\/td><td rowspan=\"2\" width=\"135\">39,0-40,0 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>120-180 min<\/b><\/td><td rowspan=\"2\" width=\"164\">60 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 3-4\u00a0<\/b><b>tundi<\/b><\/td><\/tr><tr><td width=\"155\">60-90 min<\/td><td width=\"155\">60-90 min<\/td><\/tr><\/tbody><\/table><\/div><\/div><\/div><div id=\"ut-row-inner-68e7a7d03e7dd\" class=\"vc_row wpb_row vc_inner vc_row-fluid ut-row-inner-68e7a7d03e7ec\"><div class=\"wpb_column vc_column_container vc_col-sm-6\"><div id=\"ut-column-inner-68e7a7d03eb05\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"wpb_content_element\"><div id=\"ut_bi_68e7a7d03ebdb\" class=\"bklyn-big-icon-wrap\"><div class=\"bklyn-big-icon bklyn-big-icon-square\">\u00a0<\/div><p class=\"bklyn-big-icon-title\">\u00a0<\/p><\/div><\/div><\/div><\/div><\/div><\/div><p>\u00a0<\/p><\/div><\/div><\/div><\/div><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d0149af animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"d0149af\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p>M\u00c4RKUS: see artikkel ei ole ammendav loetelu WBH wIRA uuringutest ja m\u00f5judest<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-0f3186c e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"0f3186c\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-072e6e2 elementor-widget elementor-widget-heading\" data-id=\"072e6e2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">References and Citations<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d13e67b animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"d13e67b\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><section><ol><li style=\"text-align: left;\">Ardenne M. von. Moderate Hyperthermie als Behandlungsmethode mit vielen Indikationen. \u00c4rztzeitschr Naturheilverf 1994; 5:356-61.<\/li><li style=\"text-align: left;\">B\u00e4umler H., Scherf H.P., Aurisch R., et al. Einflu\u00df einer Serie von Infrarot-Ganzk\u00f6rperbestrahlungen auf Flie\u00dfeigenschaften des Blutes und die H\u00e4modynamik. Perfusion 1990: 138-43.<\/li><li style=\"text-align: left;\">Heckel M. Ganzk\u00f6rper-Hyperthermie und Fiebertherapie, Grundlagen und Praxis. Stuttgart: Hippokrates Verlag, 1990.<\/li><li style=\"text-align: left;\">Kosaka M., Sugahara T., Schmidt K.L., Simon E. Thermotherapy: Principles and Practice. Heidelberg: Springer Verlag, 2000.<\/li><li style=\"text-align: left;\">Meffert H., Hecht H.C., G\u00fcnther H., et al. Biophysikalische Ergebnisse des klinischen Tests der IRA-Therm-Hyperthermietechnik der 2. Generation. ThermoMed 1990; 6:71-78.<\/li><li style=\"text-align: left;\">Schmidt K.L. Hyperthermie und Fieber, Wirkungen bei Mensch und Tier. 2. \u00fcberarb Aufl. Stuttgart: Hippokrates Verlag, 1987.<\/li><li style=\"text-align: left;\">Vaupel P., Kr\u00fcger W. W\u00e4rmetherapie mit wassergefilterter Infrarot-A-Strahlung, Grundlagen und Anwendungsm\u00f6glichkeiten. 2. \u00fcberarb Aufl. Stuttgart: Hippokrates Verlag, 1995.<\/li><li style=\"text-align: left;\">Piazena H., Meffert H. Optische Eigenschaften der Haut und die photobiologischen Grundlagen zur Dosierung von IR-Hautbestrahlungen in vivo und in vitro. 6. Symposium Licht und Gesundheit 2008 13.-14.03. Berlin, 2008:162-178.<\/li><li style=\"text-align: left;\">Zschaeck S. and Beck M. Chapter 8 Whole-Body Hyperthermia in Oncology: Renaissance in the Immunotherapy Era?<\/li><li style=\"text-align: left;\">Zhang H, Wang W, Zhang S, Huang W. Comparison of the anti-tumor effects of various whole-body hyperthermia protocols&#8230; Immunol Invest. 2005;34(3):245-58.<\/li><li style=\"text-align: left;\">Abreu MM, Chocron AF, Smadja DM. From cold to hot: mechanisms of hyperthermia in modulating tumor immunology for enhanced immunotherapy. Front Immunol. 2025 Feb 28;16:1487296.<\/li><li style=\"text-align: left;\">Bull JMC. et al. Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-\u03b1: A description of a phase I-II protocol. Journal of Hyperthermia. 2008; 24(8): 649-662.<\/li><li style=\"text-align: left;\">Weigelin B. Visualization of the immune effect of hyperthermia. ICHO 2021, Session: Hyperthermia and immunology.<\/li><li style=\"text-align: left;\">Faghihi Moghaddam F, Bakhshandeh M, Mofid B, et al. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone&#8230; J Therm Biol. 2024 Feb;120:103804.<\/li><li style=\"text-align: left;\">Hildebrandt B, Dr\u00e4ger J, Kerner T. et al. Whole-body hyperthermia in the scope of von Ardenne\u2019s systemic cancer multistep therapy (sCMT)&#8230; International Journal of Hyperthermia. 2004;3:317\u2013333.<\/li><li style=\"text-align: left;\">Atmaca A., Al-Batran S.E., Neumann A., et al. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer \u2013 a phase II study. Gynecol Oncol 2009; 2:384-88.<\/li><li style=\"text-align: left;\">Brockow T., Wagner A., Franke A., Offenb\u00e4cher M., Resch K.L. A Randomized Controlled Trial on the Effectiveness of Mild Water-filtered Near Infrared Whole-body Hyperthermia&#8230; Clin J Pain 2007; 1:67-75.<\/li><li style=\"text-align: left;\">Kleef R, Nagy R, Baierl A, et al. Low-dose Ipilimumab plus Nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series&#8230; Cancer Immunol Immunother. 2021;70:1393\u2013403.<\/li><li style=\"text-align: left;\">Adachi H., Katsuno M., Waza M., et al. Heat shock proteins in neurodegenerative diseases: Pathogenic roles and therapeutic implications. Int J Hyperthermia 2009; 8:647-54.<\/li><li style=\"text-align: left;\">Atmaca A., Al-Batran S.E., Neumann A., et al. Whole-body hyperthermia (WBH) in combination with carboplatin&#8230; Gynecol Oncol 2009; 2:384-88.<\/li><li style=\"text-align: left;\">Bull J.M., Scott G.L., Figueroa G., et al. An Update of a Phase II Clinical Trial Using Fever-Range Whole-Body Thermal Therapy (FR-WB-TT)&#8230; Soc for Thermal Med Joint Annual Meeting, 14.-17.5.2007.<\/li><li style=\"text-align: left;\">Bull J.M., Scott G.L., Strebel F.R., et al. Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine and daily interferon-\u03b1: A description of a phase I-II protocol. Int J Hyperthermia 2008; 8:649-62.<\/li><li style=\"text-align: left;\">Bull J.M., Nagle V.L., Scott G., et al. A phase-I-study of optimally-timed Gemcitabine + Cisplatin\/Interferon-a combined with long-duration, low-temperature whole-body hyperthermia. ESHO 2001, Verona\/ Italy, 30.05.-02.06.2001:67.<\/li><li style=\"text-align: left;\">Capitano M., Mace T., Nemeth M., et al. A novel strategy for improving neutrophil recovery following total body irradiation. Soc for Thermal Med Joint Annual Meeting, 24.-26.4.2010.<\/li><li style=\"text-align: left;\">Dayanc B.E., Ostberg J.R., Repasky E.A. Enhancement of NK Cell Cytotoxic Activity by Mild Thermal Stress. Soc of Thermal Med Annual Meeting, 6.-8.4.2006.<\/li><li style=\"text-align: left;\">Hajto T., Hostanska K. Effect of in vivo hyperthermia on human natural killer cells. Clin Trials J 1985; 6:514-20.<\/li><li style=\"text-align: left;\">Hattori T., Kokura S., Okuda T., et al. Antitumor effect of whole body hyperthermia with \u03b1-galactosylceramide in a subcutaneous tumor model of colon cancer. Int J Hyperthermia 2007; 7:591-98.<\/li><li style=\"text-align: left;\">Kisailus A., Pritchard M., Li Y., Ostberg J., Repasky E.A. Thermal Regulation of Antigen Presenting Cells: Use of Hyperthermia as an Adjuvant for Cancer Vaccines. Soc of Thermal Med Annual Meeting, 6.-8.4.2006.<\/li><li style=\"text-align: left;\">Multhoff G. Letter to Editor, Hyperthermia classic commentary: Activation of natural killer (NK) cells by heat shock protein 70&#8230; Int J Hyperthermia 2009; 3:176-79.<\/li><li style=\"text-align: left;\">Peer A.J., Grimm M.J., Zynda E.R., Repasky E.A. Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia. Immunol Res 2010; 1-3:137-154.<\/li><li style=\"text-align: left;\">Rowe R.W., Stebel F.R., Proett J.M., et al. Fever-range whole body thermotherapy combined with oxaliplatin: A curative regimen in a pre-clinical breast cancer model. Int J Hyperthermia 2010; 6:565-76.<\/li><li style=\"text-align: left;\">Schencking M., Frese T., Sandholzer H. Behandlung einer Radikulopathie bei oss\u00e4rer Metastasierung der Lendenwirbels\u00e4ule durch Infrarot-A-Ganzk\u00f6rperhyperthermie. Forsch Komplementmed 2008; 15:273-76.<\/li><li style=\"text-align: left;\">Scott G.L., Bull J.M.C., Kochn M. Management of Conscious Sedation&#8230; 9th Int Congress on Hyperthermic Oncology, 20.-24.4.2004.<\/li><li style=\"text-align: left;\">Shecterle L.M., Cyr J.A.S. Hyperthermia Aids Patients with Advanced Lung Cancer. Soc of Thermal Med Annual Meeting, 6.-8.4.2006.<\/li><li style=\"text-align: left;\">Skitzki J.J., Repasky E.A., Evans S.S. Hyperthermia as an immunotherapy strategy for cancer. Current Opnion in Investigational Drugs 2009; 6: 550-58.<\/li><li style=\"text-align: left;\">Toyota N., Strebel F.R., Stephens L.C., et al. Long-duration, mild whole body hyperthermia with cisplatin: tumour response and kinetics of apoptosis and necrosis&#8230; Int. J. Hyperthermia 1997; 5:497-506.<\/li><li style=\"text-align: left;\">Wang X.Y., Kazim L., Repasky E.A., Subjeck J.R. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines&#8230; J of Immunology 2001; 165:490-97.<\/li><li style=\"text-align: left;\">VanderZee J., DeBruijne M., Mens J.W.M., et al. Reirradiation combined with hyperthermia in breast cancer recurrences&#8230; Int J Hyperthermia 2010; 7:638-48.<\/li><li style=\"text-align: left;\">Zagar T.M., Oleson J.R., Vujaskovic Z., et al. Hyperthermia for locally advanced breast cancer. Int J Hyperthermia 2010; 7:618-24.<\/li><li style=\"text-align: left;\">Zagar T.M., Oleson J.R., Vujaskovic Z., et al. Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence&#8230; Int J Hyperthermia 2010; 7: 612\u201317.<\/li><li style=\"text-align: left;\">Sen A., Capitano M., Dommer M., et al. Thermoregulatory responses to mild systemic thermal stress increase tumor perfusion&#8230; Cancer Res. 2011; 71(11):3872-3880.<\/li><li style=\"text-align: left;\">Koska J., Rovensky J., Zimanova T., Vigas M. Growth hormone and prolactin responses during partial and whole body warm-water immersions. Acta Physiol Scand. 2003 May;178(1):19-23.<\/li><li style=\"text-align: left;\">Vigas M., Rovensky J., Zimanova T., Koska J. Responses of growth hormone and prolactin to local and whole-body application of Piestany mud. Acta Rheumatol et Balneol Pistiniana 2002:31-38.<\/li><li style=\"text-align: left;\">Meffert B., Hochmuth O., Steiner M. Effects of a multiple mild infrared a induced hyperthermia on central and peripheral pulse waves in hypertensive patients. North Sea Conference on Biomedical Engineering 1990.<\/li><li style=\"text-align: left;\">Meffert H., Scherf HP., Meffert B. Milde Infrarot-A-Hyperthermie. Auswirkungen von Serienbestrahlungen mit wassergefilterter Infrarotstrahlung&#8230; Akt Dermatol 1993; 19:142-48.<\/li><li style=\"text-align: left;\">Applegate L.A., Scaletta C., Panizzon R., et al. Induction of the putative protein ferritin by infrared radiation: Implications in skin repair. Int J of Molecular Med 2000; 5:247-51.<\/li><li style=\"text-align: left;\">Scherf H.P., Meffert H., B\u00e4umler H., et al. Wirkung einer einmaligen milden Infrarot-A-Hyperthermie auf K\u00f6rpertemperatur, Herzfrequenz, Blutdruck und Blutviskosit\u00e4t&#8230; Dermatol Monatsschr 1989; 175:733-40.<\/li><li style=\"text-align: left;\">Streffer C. Metabolic changes during and after hyperthermia. Int J Hyperthermia 1985; 4:305-319.<\/li><li style=\"text-align: left;\">F\u00f6rster J., Fleischanderl S., Wittstock S., et al. Infrared-Mediated Hyperthermia is Effective in the Treatment of Scleroderma-Associated Raynaud\u2019s Phenomenon. J of Investigative Dermatology 2005; 6:1313-16.<\/li><li style=\"text-align: left;\">Koska J., Rovensky J., Zimanova T., et al. Sympathoadrenal regulation of circulatory responses to whole-body hyperthermia&#8230; Acta Rheumatol et Balneol Pistiniana 2002:23-30.<\/li><li style=\"text-align: left;\">Janssen C.W., Lowry C.A., Mehl M.R., et al. Whole-Body Hyperthermia for the Treatment of Major Depressive Disorder \u2013 A Randomized Clinical Trial. JAMA Psychiatry. 2016 May 12.<\/li><li style=\"text-align: left;\">Tarner I.H., Ladner U.M., Uhlemann C., Lange U. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1 beta and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol 2009; 4:397-402.<\/li><li style=\"text-align: left;\">Ettrich U., Konrad B., Prate K., et al. Milde Ganzk\u00f6rperhyperthermie in Kombination mit station\u00e4rer multimodal orientierter Schmerztherapie&#8230; Orthop\u00e4de 2014; 2:165-74.<\/li><li style=\"text-align: left;\">Weller E., Ullrich D. Infrarot-A-Hyperthermie-Anwendung bei Patienten mit Analgetica-Abusus wegen chronischer R\u00fcckenschmerzen. Vortrag auf dem 95. Kongre\u00df der Gesellschaft f\u00fcr Phys Med und Rehab 5.10.1990.<\/li><li style=\"text-align: left;\">Morf S., Vesti B.A., Forster A., et al. Microcirculation abnormalities in patients with fibromyalgia \u2013 measured by capillary and laser fluxmetry. Arthritis Res Ther 2005; 7:R209-16.<\/li><li style=\"text-align: left;\">Walz J., Hinzmann J., Haase I., Witte T. Ganzk\u00f6rperhyperthermie in der Schmerztherapie \u2013 eine kontrollierte Studie an Patienten mit Fibromyalgiesyndrom. Schmerz 2013; 27:38-45.<\/li><li style=\"text-align: left;\">Romeyke T., Stummer H. Multi-modal pain therapy of fibromyalgia syndrome with integration of systemic whole-body hyperthermia&#8230; J Musculoskel Pain 2014; 4:341-55.<\/li><li style=\"text-align: left;\">Zauner D., Quehenberger F., Hermann J., et al. Whole body hyperthermia treatment increases interleukin 10 and toll-like receptor 4 expression in patients with ankylosing spondylitis: A pilot study. Int J Hyperthermia 2014; 6:393-401.<\/li><li style=\"text-align: left;\">Lange U., M\u00fcller-Ladner U., Dischereit G. Wirkung iterativer Ganzk\u00f6rperhyperthermie mit wassergefilterter Infrarot-A-Strahlung bei ankylosierender Spondylitis&#8230; Akt Rheumatol 2017; 2:122-128.<\/li><\/ol><\/section><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-97dc368 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"97dc368\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><section><p>\u00a0<\/p><\/section><footer>\u00a9 <time>2025<\/time> Romanian Society Oncologic Hyperthermia All rights reserved. Source: Analysis based on scientific literature.<\/footer><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Kogu Keha H\u00fcpertermia (WBH) Onkoloogias ja Muudes Patoloogiates: Konsolideeritud S\u00fcnergia, Immunomoduleerimine ja Kliinilised uuringud Avaldatud:\u00a02025-10-13\u00a0| Viimati Muudetud:\u00a02025-10-13 Autorid: Veronica Iatan, M.D., Cristian Gologan, M.Sc. Kogu Keha H\u00fcpertermia (WBH) on s\u00fcsteemne onkoloogiline strateegia, mis h\u00f5lmab keha keskse temperatuuri kontrollitud t\u00f5stmist, sageli kasutades Veega Filtreeritud Infrapuna-A (wIRA) tehnoloogiat. WBH on peamiselt Kemo\/Radio-sensibilisaator, mis parandab oluliselt kasvaja perfusiooni<br \/><a class=\"moretag\" href=\"https:\/\/ardenneiratherm.com\/et\/kliinilised-uuringud-hupertermia-onkoloogias\/\">+ Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/page-fullwidth_template.php","meta":{"footnotes":""},"class_list":["post-976","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/ardenneiratherm.com\/et\/wp-json\/wp\/v2\/pages\/976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ardenneiratherm.com\/et\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ardenneiratherm.com\/et\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ardenneiratherm.com\/et\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ardenneiratherm.com\/et\/wp-json\/wp\/v2\/comments?post=976"}],"version-history":[{"count":0,"href":"https:\/\/ardenneiratherm.com\/et\/wp-json\/wp\/v2\/pages\/976\/revisions"}],"wp:attachment":[{"href":"https:\/\/ardenneiratherm.com\/et\/wp-json\/wp\/v2\/media?parent=976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}